Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
07:05am, Monday, 05'th Apr 2021
CARLSBAD, Calif., April 5, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced the initiation of a Phase 3 clinical trial of ION363 in patients with amyotrophic lateral sc
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
11:07pm, Wednesday, 31'st Mar 2021
New York, New York--(Newsfile Corp. - March 31, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such inve
Ionis Pharmaceuticals: Recent Setback Offers An Interesting Opportunity
09:30am, Wednesday, 31'st Mar 2021
Ionis Pharmaceuticals is at a crossroads. The pipeline begins to take form with a recent setback creating a waterfall dive in the share price.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc. - IONS
03:05am, Tuesday, 30'th Mar 2021
NEW YORK, March 30, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ionis Pharmaceuticals, Inc. ("Ionis" or the "Company") (NASDAQ: IONS). Such investors ar
Ionis Pharma's Ligand-Conjugated Antisense Hits Primary Endpoint Goal In Hereditary Angioedema Study
11:30am, Monday, 29'th Mar 2021
Ionis Pharmaceuticals Inc (NASDAQ: IONS) has announced data from a Phase 2 study evaluating IONIS-PKK-LRx in patients with hereditary angioedema (HAE). The study met its primary and secondary endp
Ionis reports positive topline Phase 2 study results of its novel antisense treatment for hereditary angioedema
07:05am, Monday, 29'th Mar 2021
CARLSBAD, Calif., March 29, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that data from a Phase 2 clinical study of IONIS-PKK-LRx met its primary and secondary endp
Ionis to present at upcoming investor conferences
07:05am, Friday, 26'th Mar 2021
CARLSBAD, Calif., March 26, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in RNA-targeted therapeutics, today announced that management will participate in virtual firesi
DDD, AONE, RAVN, ION: 4 Stocks That Cathie Wood's ARK Funds Are Betting On Today
12:28pm, Wednesday, 24'th Mar 2021
Cathie Wood's Ark Invest continues to add more shares to its holdings with it picking out a few companies worth noting on Wednesday. The post DDD, AONE, RAVN, ION: 4 Stocks That Cathie Wood's ARK Fund
Here's Why Ionis Pharmaceuticals Stock Got Slammed Today
06:22pm, Tuesday, 23'rd Mar 2021
The biotech's partner is stopping a late-stage clinical trial for a Huntington's disease treatment.
Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails
09:05am, Tuesday, 23'rd Mar 2021
Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.
Ionis, 3D Systems, Unity, BYD, Deere — What Cathie Wood's Ark Bought And Sold Today
11:43pm, Monday, 22'nd Mar 2021
Every night, Cathie Wood's Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause c
Ionis' partner provides update on clinical studies evaluating tominersen (IONIS-HTT Rx)
04:01pm, Monday, 22'nd Mar 2021
CARLSBAD, Calif., March 22, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced its partner, Roche, has decided to discontinue dosing in the Phase III GENERATION HD1 study of to
Ionis establishes new grant program to advance research and understanding of transthyretin amyloidosis
07:05am, Monday, 01'st Mar 2021
CARLSBAD, Calif., March 1, 2021 /PRNewswire/ -- Ionis Pharmaceuticals (NASDAQ: IONS) today announced that the company has launched a new grant program that provides funding to U.S.-based researchers w
IONS Stock Price: $55 Target (Down From $60) By Piper Sandler
09:25pm, Saturday, 27'th Feb 2021
Shares of Ionis Pharmaceuticals Inc (NASDAQ: IONS) has received a price target decrease from $60 to $55 by Piper Sandler. These are the details.
Ionis (IONS) Q4 Earnings Decline Y/Y, Sales Beat Estimates
09:08am, Thursday, 25'th Feb 2021
Ionis (IONS) Q4 adjusted earnings decline year over year. The company issues guidance for 2021.
